George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Erm the pipeline and expected growth cant even be compared to Glaxo. Dividend is not diminishing they didnt decrease it? The interim dividend declared is actually more. Profits take precedence for most companies you will find. EPS is growing nicely too.
But it is true vaccine optimism has dented the share price. Last few days recovery stocks like restaurant group, iag etc has made gains, whilst big caps and defensive stocks are dropping (also because the pound strength). The business is still good, it will go up again on the bit of next good news as always.
Totally agree. I can see from my portfolio my big caps and defensives down, but recovery stocks up (like restaurant group, dunelm, hammerson, lamd sec, iag). Unfortunately I have more big caps and defensive stocks right now!
Therefore I conclude this price drop is not permanent whilst people adjust portfolips to recovery stocks...
Agreed its undervalued. Great pipelines and lots of approvals recently (lile Forxiga this morning). The only thing weighing on sentiment is its recent acquisition of Alexion. Its in theory a great deal, but one can argue Astra is paying a premium. Depends how you look at it in terms of how confident you think Astra can market and transform Alexions pipeline.
The debt to asset ratio is on par with most pharma companies, dont believe what some others are spouting about Astras debt. Have to take into account their assets as well.
Definitely undervalues. Noticed Forxiga got approved this morning on China. Massive market. No ones noticing the number of approvals they had in the last few months as vaccine is taking away attention even though it has no impact on their financials.
The vaccine should have no bearing on the share price as its non profit so therefore its not the portfolios. When the EMA and MHRA are happy thats sufficient. Watch the UK rates go right down before Europe the next few weeks to vindacate the decision. Results will prove this anyways so their loss
Erm not a long term downtrend when it was close to 80 a week ago. Its called short term movement. Not sure what you classify long when over the last 7 years its been up. You can ignore the vaccine hype when it drove the sp to 100.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268
Posting the actual abstract for reading would have been more useful.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268
And theres the lancet evidence which im sure will be critiqued by the community
But the post is skewed and does not account for the fact AZN did have evidence for the elderly (antibodies) and the drug regulatory bodies were comfortable for over 65 approval.
The evidence is in favour and the final pieces of data will follow. What we are doing in the UK will also generate data for the Pfizer vaccine spacing out doses but scientific principal in immunology makes sense to do it for all vaccines.
There is now evidence on prevention of transmission in their new data which will be officially published in medical circles soon.
The over 65 data is coming but there is already good enough evidence to know it stimilates antibodies in the elderly to know it works. Its a matter of opinion and the data will back that up soon. When the MHRA, EMA and a load of other healthcare agencies approve it for over 65 use the overwelming consensus its fine. Other European healthboards may have different opinions but thw regulatory bodiea is all it matters.